Makowska, Zuzanna. Interferon signalling in the liver : implications for the natural course and therapy of hepatitis C. 2012, PhD Thesis, University of Basel, Faculty of Science.
Official URL: http://edoc.unibas.ch/diss/DissB_10186
Interferon-based therapies are in clinical use for treatment of diseases such as hepatitis C virus infection or multiple sclerosis. Interferon-induced regulators of the Jak-STAT signalling are known to involve in negative feedback loops and affect the response to exogenously administered interferon alpha. In this context it is important to understand which interferon subtypes are potent inducers of the negative regulators and whether all interferons are equally sensitive to the inhibitory mechanisms. To tackle this question we attempted to characterize and compare response patterns to interferons alpha, beta and lambda in a setting of continuous and repeated stimulation (see Section 3.1).
The acute phase of hepatitis C virus infection in humans (first 6 months after transmission) is characterized by high rates of spontaneous clearance and excellent treatment response (>90% cure rate). As the infection at that stage is mostly asymptomatic, it is rarely diagnosed and, in comparison to the chronic phase of hepatitis C virus infection, little is known about the human liver response to acute hepatitis C virus infection and the host-virus interactions during this time. In the second part of this PhD project we made use of the acute hepatitis C liver biopsies collected over the course of several years at the University Hospital of Basel to describe human hepatic response to acute hepatitis C virus infection and gain an insight into the mechanism of improved cure rate compared to chronic hepatitis C (see Section 3.2).
Chronic hepatitis C is currently treated with combination therapies based on pegylated interferon- alpha. A significant proportion of patients fails to respond to the current treatment options, probably due to the refractory state of the preactivated endogenous interferon system in the liver. Several compounds are currently in clinical development with the aim to improve the treatment outcome of pegylated interferon�alpha nonresponders. In the last part of this work we investigated in vivo the mode of action
of a novel synthetic TLR9 agonist which is a clinical candidate for anti-hepatitis C virus therapy
and characterized the hepatic response to this compound (see Section 3.3).
|Advisors:||Heim, Markus Hermann|
|Committee Members:||Bumann, Dirk|
|Faculties and Departments:||05 Faculty of Science > Departement Biozentrum > Infection Biology > Molecular Microbiology (Bumann)|
|Bibsysno:||Link to catalogue|
|Number of Pages:||101 S.|
|Last Modified:||30 Jun 2016 10:51|
|Deposited On:||26 Nov 2012 14:28|
Repository Staff Only: item control page